Rafael Amado
CIK 1662119 · See Remarks · last filed 2026-04-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.76M
Companies
5
Total Filings
44
Lifetime Open-Market Net
-$3.73M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZLAB | See Remarks | 57,022 | $17.07 | $973.4K | -$2.10M | 18 | 2026-04-08 |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 3 | 2025-01-08 |
| ALLO | EVP of R&D | 541,946 | $1.90 | $1.03M | -$1.59M | 16 | 2022-10-11 |
| ASND | President, R&D | 17,237 | $218.06 | $3.76M | -$39.0K | 6 | 2019-08-07 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Medical Officer | — | $0.06 | — | $0 | 1 | 2016-01-20 |
Recent Filings · Page 5 of 5
44 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-07 | ASND | Grant (A) | — | $0 | EDGAR |
| 2018-01-17 | ASND | Grant (A) | — | $0 | EDGAR |
| 2017-01-18 | ASND | Grant (A) | — | $0 | EDGAR |
| 2016-01-20 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–44 of 44
Prev
Page 5 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.